What is Anti-diabetic Medication Market?
Anti-diabetic medications are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Anti-diabetic medications are commonly used to manage diabetes. Anti-diabetic medications are all pharmacological agents that have been approved for hyperglycemic treatment in diabetes mellitus. The increasing prevalence of diabetes across the globe will stimulate the market potential for anti-diabetic medication during the forecast period.
The market study is being classified by Type (Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin] and Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]), by Application (Prevent and Treatment Diabetes, Obesity Treatment, Cardiovascular Protection and Others) and major geographies with country level break-up.
AstraZeneca plc (United Kingdom), Bayer AG (Germany), C.H. Boehringer Sohn AG & Ko. KG (Germany), Bristol-Myers Squibb (United States), Eli Lilly (United States), Halozyme Therapeutics (United States), Johnson & Johnson (United States), Merck & Co. Inc. (United States), Novartis AG (Switzerland) and Pfizer Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Novo Nordisk (Denmark), Oramed Pharmaceuticals Inc. (Israel), Sanofi (France) and Takeda Pharmaceutical (Japan).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Anti-diabetic Medication market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Anti-diabetic Medication market by Type, Application and Region.
On the basis of geography, the market of Anti-diabetic Medication has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rising Prevalence of Chronic Diseases like Diabetes across the Globe
- Growing Prevalence of Lifestyle-Induced Disorders such as Obesity
- Increasing Adoption of Oral Antidiabetic Drugs
- Prohibitive Cost of Insulin
- Rising Spending on Research and Development for Innovative Drugs
- Safety Issues Pertaining to Some Diabetic Drugs
Market Leaders and some development strategies
In February 2018, Cipla collaborated with Novartis and Johnson & Johnson to market their anti-diabetic drugs. This collaboration has led to the business expansion of the firm thereby strengthening its market position.
In December 2019, Mankind Pharmaceuticals signed a collaborative marketing agreement with Glenmark Pharmaceuticals to market remoglifozin, an antidiabetic drug, in India. This has allowed both firms to expand their business in the Asia Pacific region.
Key Target AudienceAnti-diabetic Medication Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase